Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy
Clinical trial NCT05028634 · COMPLETED
Trial details
- NCT number
- NCT05028634
- Sponsor
- Celgene
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-11
- Primary completion
- 2023-11-15
- Enrollment
- 63
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.